About: Amarin Corporation   Sponge Permalink

An Entity of Type : dbkwik:resource/41M8fembgW4ejRUqT-lkRA==, within Data Space : 134.155.108.49:8890 associated with source dataset(s)

Amarin Corporation (NASDAQ: AMRN) is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa (AMR-101) which is a prescription grade omega-3 fatty acid. In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD. Amarin CEO Joe Zakrzewski has said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States. Recently on July 26th, 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval. Vascepa will also be a key competitor against GlaxoSmithKline's Lovaza.

AttributesValues
rdf:type
rdfs:label
  • Amarin Corporation
rdfs:comment
  • Amarin Corporation (NASDAQ: AMRN) is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa (AMR-101) which is a prescription grade omega-3 fatty acid. In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD. Amarin CEO Joe Zakrzewski has said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States. Recently on July 26th, 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval. Vascepa will also be a key competitor against GlaxoSmithKline's Lovaza.
sameAs
Products
  • Vascepa
dcterms:subject
foaf:homepage
dbkwik:speedydelet...iPageUsesTemplate
num employees
  • 50(xsd:integer)
Foundation
  • 1993(xsd:integer)
Traded as
  • : http://www.nasdaq.com/symbol/AMRN)
Company Name
  • Amarin Corporation
Homepage
Industry
company type
  • Public
concern
  • no indication of meeting WP:ORG notability guidelines. Only independent reference is to a mover of the day video. Google searches not finding any significant coverage.
Timestamp
  • 20120726234605(xsd:double)
company logo
  • 250(xsd:integer)
Location
  • Bedminster New Jersey U.S.
abstract
  • Amarin Corporation (NASDAQ: AMRN) is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa (AMR-101) which is a prescription grade omega-3 fatty acid. In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD. Amarin CEO Joe Zakrzewski has said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States. Recently on July 26th, 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval. Vascepa will also be a key competitor against GlaxoSmithKline's Lovaza.
Alternative Linked Data Views: ODE     Raw Data in: CXML | CSV | RDF ( N-Triples N3/Turtle JSON XML ) | OData ( Atom JSON ) | Microdata ( JSON HTML) | JSON-LD    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3217, on Linux (x86_64-pc-linux-gnu), Standard Edition
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2012 OpenLink Software